A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent

Inclusion Criteria:

• Participants with relapsed and refractory multiple myeloma (as per InternationalMyeloma Working Group [IMWG] definitions) whose prior therapy included a proteasomeinhibitor and an immunomodulatory agent, being newly initiated on DARZALEX (daratumumab) monotherapy based on independent clinical judgment of treatingphysicians as per locally approved prescribing information

• Each participant (or their legally acceptable representative) must sign an informedconsent form (ICF) indicating that he or she understands the purpose of andprocedures required for the study and are willing to participate in the study.Participants must be willing and able to adhere to the prohibitions and restrictionsspecified in this protocol, as referenced in the informed consent form (ICF)

Exclusion Criteria:

• Participants who are not eligible to receive DARZALEX as per the locally approvedprescribing information

• Participant participating or planning to participate in any interventional drugtrial during the course of this study

• Known seropositive for human immunodeficiency virus (HIV)

• Seropositive for hepatitis B (defined by a positive test for hepatitis B surfaceantigen [HBsAg]). Participants with resolved infection (that is, participants whoare HBsAg negative but positive for antibodies to hepatitis B core antigen [anti-HBc] and/or antibodies to hepatitis B surface antigen [anti-HBs]) must bescreened using real-time polymerase chain reaction (PCR) measurement of hepatitis Bvirus (HBV) deoxyribonucleic acid (DNA) levels. Those who are PCR positive will beexcluded. exception: Participants with serologic findings suggestive of HBVvaccination (anti-HBs positivity as the only serologic marker) and a known historyof prior HBV vaccination, do not need to be tested for HBV DNA by PCR

• Known seropositive for hepatitis C (except in the setting of a sustained virologicresponse [SVR], defined as aviremia at least 12 weeks after completion of antiviraltherapy)